Combining BioAccord, our most capable MS detection platform, with ACQUITY Premier UPLC, our highest performance LC system, to demonstrate superior performance.
One scientist at a major global pharma company estimated that an analytical method could see up to 100 transfers in its lifetime. Increasingly, such transfers will take place across geographic borders. How ready are you to mobilize your methods?
Is your analytical method bound for the lab down the hall, or the lab halfway around the world? If you’re an analytical or QC scientist, get ready for more method transfers between organizations. We explore the complexities of analytical method transfer in part 2 of our ongoing series.
There’s a new analytical testing landscape taking shape, and it’s having a big effect on how we develop, transfer, and update methods. Data quality and business efficiency are both at stake. Are you ready?
If data can throw your biotherapeutic development program into chaos, it can also help move you forward. Let’s see how.
As regulators focus in on the critical quality attributes of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations – other than to run more assays?
The thought of transferring established high performance liquid chromatography (HPLC) methods onto a another vendor’s LC, or a new platform like UHPLC/UPLC, may cause a bit of anxiety for those that may be unaware of… Read more >